Tachycardia After a Heart Failure Hospitalization. Another Piece of the Puzzle?*.

JACC: Heart Failure

Volumn 1, Issue 6, 2013, Pages 497-499

  Metra, Marco ^a  

^a University and Civil Hospital of Brescia   (Italy)

Author keywords

Heart failure; Heart rate; Hospitalization; Mortality; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; IVABRADINE;

CARDIOVASCULAR MORTALITY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TACHYCARDIA; TREATMENT OUTCOME; FEMALE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY;

FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE;

EID: 84888999919     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.10.003     Document Type: Editorial

References (27)

1. Kannel W.B., Kannel C., Paffenbarger R.S., Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987, 113:1489-1494.
2. Tverdal A., Hjellvik V., Selmer R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40-45 years. Eur Heart J 2008, 29:2772-2781.
3. Fox K.M., Ferrari R. Heart rate: a forgotten link in coronary artery disease?. Nat Rev Cardiol 2011, 8:369-379.
4. Dobre D., Borer J.S., Fox K., et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail 2013 Aug 7, [E-pub ahead of print].
5. Fox K., Ford I., Steg P.G., et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372:817-821.
6. Bohm M., Swedberg K., Komajda M., et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010, 376:886-894.
7. Metra M., Torp-Pedersen C., Swedberg K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005, 26:2259-2268.
8. Greene S.J., Vaduganathan M., Wilcox J.E., et al. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST trial. J Am Coll Cardiol HF 2013, 1:488-496. on behalf of the EVEREST Trial Investigators.
9. Gheorghiade M., Vaduganathan M., Fonarow G.C., Bonow R.O. Rehospitalization for heart failure: problems and perspectives. JAm Coll Cardiol 2013, 61:391-403.
10. Gheorghiade M., Pang P.S., Ambrosy A.P., et al. Acomprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev 2012, 17:485-509.
11. Milo-Cotter O., Cotter-Davison B., Lombardi C., et al. Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology 2011, 119:96-105.
12. Broqvist M., Dahlstrom U., Karlberg B.E., Karlsson E., Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J 1989, 10:1075-1083.
13. Bristow M.R. Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011, 109:1176-1194.
14. O'Connor C.M., Mentz R.J., Cotter G., et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur J Heart Fail 2012, 14:605-612.
15. Bui A.L., Grau-Sepulveda M.V., Hernandez A.F., et al. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J 2013, 165:567-574, e6.
16. Abraham W.T., Fonarow G.C., Albert N.M., et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). JAm Coll Cardiol 2008, 52:347-356.
17. O'Connor C.M., Abraham W.T., Albert N.M., et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008, 156:662-673.
18. Metra M., Cotter G., Davison B.A., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. JAm Coll Cardiol 2013, 61:196-206.
19. Metra M., Nodari S., Parrinello G., et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 2007, 9:776-786.
20. Metra M., Gheorghiade M., Bonow R.O., Dei Cas L. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation 2010, 122:1782-1785.
21. Kolloch R., Legler U.F., Champion A., et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008, 29:1327-1334.
22. Reil J.C., Tardif J.C., Ford I., et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JAm Coll Cardiol 2013, 62:1977-1985.
23. Reil J.C., Hohl M., Reil G.H., et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 2013, 34:2839-2849.
24. Fox K., Komajda M., Ford I., et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013, 34:2263-2270.
25. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
26. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012, 14:803-869.
27. Castagno D., Petrie M.C., Claggett B., McMurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012, 33:1137-1141.